Stock Events

Stock Events

Myrexis

$0

2

-$0-33.33% Monday 13:30

Statistics

Day High

0

Day Low

0

52W High

0.01

52W Low

0

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Dividends

0%Dividend Yield

Feb 13

$2.86

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

10FebExpected

Q2 2021

Q3 2021

Q4 2021

Q1 2022

Q2 2022

Q3 2022

Q4 2022

0

0.33

0.67

1

Expected EPS

0

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2012

2013

0Revenue

-11.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYRX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and markets drugs in similar therapeutic areas as Myrexis, making them direct competitors in the pharmaceutical market.

Amgen focuses on human therapeutics and biologics, operating in the same biotech space as Myrexis, with overlapping drug development programs.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines that address serious diseases, similar to Myrexis' objectives.

Pfizer is a large pharmaceutical company with a broad range of drug therapies that compete with Myrexis' products in various therapeutic areas.

Merck operates globally in pharmaceuticals and offers products that directly compete with Myrexis in the oncology and acute care sectors.

Eli Lilly and Company develops and manufactures pharmaceutical products in areas that overlap with Myrexis' research and development, particularly in oncology.

AbbVie is a research-based biopharmaceutical company with a strong emphasis on innovation in therapeutic areas that compete with Myrexis.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with Myrexis in the field of biotechnology and drug development.

Vertex Pharmaceuticals

Vertex Pharmaceuticals engages in creating new possibilities in medicine to cure diseases and improve people's lives, similar to Myrexis' mission in the biotech industry.

Novartis is a global healthcare company that produces drugs that directly compete with Myrexis in multiple therapeutic areas, including advanced therapies.

About

Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

Show more...

CEO

Mr. Jonathan M. Couchman CFA

Employees

1

Country

United States

ISIN

US62856H1077

Listings

0 Comments

Share your thoughts

FAQ

What is Myrexis stock price today?▼

The current price of MYRX is $0 USD — it has decreased by -33.33% in the past 24 hours. Watch Myrexis stock price performance more closely on the chart.

What is Myrexis stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Myrexis stocks are traded under the ticker MYRX.

What is Myrexis revenue for the last year?▼

Myrexis revenue for the last year amounts to 0 USD.

What is Myrexis net income for the last year?▼

MYRX net income for the last year is -11.62M USD.

Does Myrexis pay dividends?▼

Yes, MYRX dividends are paid en. The last dividend per share was 2.86 USD. As of today, Dividend Yield (FWD)% is 0%.

How many employees does Myrexis have?▼

As of May 06, 2026, the company has 1 employees.

In which sector is Myrexis located?▼

Myrexis operates in the Health & Wellness sector.

When did Myrexis complete a stock split?▼

Myrexis has not had any recent stock splits.

Where is Myrexis headquartered?▼

Myrexis is headquartered in New York, United States.